A new study testing Amarantus Diagnostics’ MSPrecise on multiple sclerosis patients identified the test as a specific and sensitive diagnostic test for multiple sclerosis. The test accurately diagnosed 84% of multiple sclerosis patients from a broad range of subjects with potential neurological diseases. These results further support Amarantus Diagnostics’ ability to design next generation sequencing (NGS) molecular diagnostics to test for disease.
“MSPrecise scoring is a powerful approach to aid clinicians in this task,” said Colin Bier, Chief Development Officer of Amarantus Diagnostics, in information provided to Multiple Sclerosis News Today. “In this study completed in 2013 and now reported in ‘GENE,’ there is an overall MSPrecise accuracy of 84% in identifying relapsing-remitting multiple sclerosis (RRMS) patients or patients that will develop RRMS, which represents a huge benefit to physicians.”
Continue
